The challenge Novo Nordisk faces in China underscores a bigger shift in the Chinese biopharma industry.
Illustration by Sam Ward
Novo Nordisk is feeling good about China. In March, the pharmaceutical company behind the blockbuster diabetes-turned-weight loss drug Ozempic held its “Capital Markets Day” presentations and held a breakout session devoted to its strong showing and trajectory in China. As Maziar Mike Doustdar, head of international operations, put it “all of our competitors combined are not able to cover what we do.”
He had good reason to be cocky: Novo Nordisk’s sales of Ozempic in China doubl
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from Andrew Peaple.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
The Concordia AI founder explains how Beijing is looking to regulate and pace AI's development while making sure it keeps up in the global race, and talks about the prospects of the U.S. and China...
Goldman Sachs economists argue that by allowing the renminbi to appreciate by 3-5 percent a year, Beijing can reconcile seemingly contradictory policy goals.
Corporate Risk Intelligence for National Security, Compliance & Due Diligence
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
